// App-Quantinova.ai

377 : AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects

Researchers

Presenter

  • Claire Galand

Principal Investigators

  • Marilyn Marques

  • James Strauss

  • Richard Carvajal

  • Min Lim

  • Benjamin Morin

  • Olga Ignatovich

  • Mark Findeis

  • Dennis Underwood

  • Marc Van Dijk

  • Irina Shapiro

  • Lernik Ohanjanian

  • Anna Wijatyk

  • Nicholas Wilson

  • Jennifer Buell

  • Dhan Chand

  • David Savitsky

  • Anthony Tolcher

Medical Centers

  • Agenus Inc, Lexington, MA, USA

  • Mary Crowley Cancer Research Centers, Dallas, TX

  • Columbia University Medical Center, New York, NY

  • AgenTus Therapeutics, Inc., Cambridge, UK

  • Gilead Sciences, San Carlos, CA, USA

  • Next Oncology, San Antonio/TX/US

Locations

  • United States

  • United Kingdom

Companies

  • Agenus Inc.

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Urelumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved